Real-time stock price, financial statements, consensus target price, insider trading, and technical analysis for Fuso Pharmaceutical Industries, Ltd. (4538:JPX), powered by AI.
Fuso Pharmaceutical Industries, Ltd. is currently trading at ¥2,057. View real-time AI analysis on Alpha Lenz.
View the latest insider trading data for Fuso Pharmaceutical Industries, Ltd. on Alpha Lenz.
Fuso Pharmaceutical Industries, Ltd.'s P/E ratio is -5.3.
“Fuso Pharmaceutical Industries, Ltd. trades at a P/E of -5.3 (undervalued) with modest ROE of -9.4%.”
Ask for details →Fuso Pharmaceutical Industries, Ltd. is a well-established company engaged in the research, development, manufacturing, and distribution of pharmaceuticals and medical products. Headquartered in Japan, Fuso focuses on producing a diverse range of pharmaceutical products including ethical drugs, generic drugs, and over-the-counter medications. The company is committed to advancing healthcare solutions that meet the evolving needs of global communities. Fuso Pharmaceutical serves various sectors, including hospitals, clinics, and pharmacies, providing essential medications that contribute to the broader healthcare ecosystem. The organization's role in the pharmaceutical industry is significant, as it aligns its operational strategies with advancements in medical technology to enhance patient care and therapeutic outcomes. By maintaining high standards in production and ensuring compliance with rigorous quality controls, Fuso Pharmaceutical Industries continues to play a vital role in the global healthcare market.
“Fuso Pharmaceutical Industries, Ltd. trades at a P/E of -5.3 (undervalued) with modest ROE of -9.4%.”
Ask for details →Fuso Pharmaceutical Industries, Ltd. (ticker: 4538) is a company listed on JPX in the Healthcare sector (Drug Manufacturers - Specialty & Generic). It has approximately 1,370 employees. Market cap is $17.6B.
The current price is 2,057 with a P/E ratio of -5.34x and P/B of 0.53x.
ROE is -9.43% and operating margin is 6.82%. Annual revenue is $60.6B.